Antagonist Of Corticotrophin Releasing Hormone As Therapeutic Agents For The Prevention Of Premature Birth In Humans
Funder
National Health and Medical Research Council
Funding Amount
$376,650.00
Summary
In developed countries the most common cause of the death of a newborn baby is premature delivery. Pre-term delivery remains the greatest cause of neonatal mortality in the western world and a major consumer of health dollars (approx. $5-7B per year in the US alone). However, a delay in the onset of labour from 20 to 25 weeks has been shown to result in a 55% greater probability of infant survival (550 fewer deaths per 1000). This project will allow: The development of new drugs that will allow ....In developed countries the most common cause of the death of a newborn baby is premature delivery. Pre-term delivery remains the greatest cause of neonatal mortality in the western world and a major consumer of health dollars (approx. $5-7B per year in the US alone). However, a delay in the onset of labour from 20 to 25 weeks has been shown to result in a 55% greater probability of infant survival (550 fewer deaths per 1000). This project will allow: The development of new drugs that will allow the extension of pregnancy term The development of protocols that will in turn reduce neonatal mortality. Additionally we believe that these new agents will be useful in preventing the onset of labour after fetal surgery. Currently there are no effective treatments capable of substantially changing delivery dates. Available therapeutics delay the onset of labour, at best, 24 hours. However, recent exciting results from our laboratories show that rising concentrations of the placental peptide Corticotrophin Releasing Hormone (CRH) are associated with the onset of labour. Further, we have also delayed the onset of labour in pregnant sheep by infusing a relatively insoluble CRH antagonist into the sheep fetus. Labour commenced ONLY AFTER the drug was withdrawn from the mother. This project builds upon an interdisciplinary team: medicinal chemists, molecular modellers, pharmacologists and endocrinologists, to further develop an exciting Australian discovery. Successful completeion of this research will, for the first time, allow the control of pregnancy duration MAXIMISING the benefits to mother and child, reducing mortality and later life morbidities typically associated with premature birth.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC230100027
Funder
Australian Research Council
Funding Amount
$5,000,000.00
Summary
ARC Training Centre in Plant Biosecurity. The ARC Training Centre in Plant Biosecurity aims to deliver a solution for Australia’s increasing biosecurity risk through generational change in its workforce coupled with breakthrough technologies. It will launch an innovative training program for future leaders who will build relationships with end users and engage meaningfully with communities for effective implementation strategies. Expected outcomes include a cohort of highly skilled graduates tha ....ARC Training Centre in Plant Biosecurity. The ARC Training Centre in Plant Biosecurity aims to deliver a solution for Australia’s increasing biosecurity risk through generational change in its workforce coupled with breakthrough technologies. It will launch an innovative training program for future leaders who will build relationships with end users and engage meaningfully with communities for effective implementation strategies. Expected outcomes include a cohort of highly skilled graduates that will innovate novel diagnostic technologies, enable data-driven decision platforms and address barriers to biosecurity adoption. This suite of graduates and technologies will transform the plant biosecurity sector to protect Australia’s $5.7 trillion natural and productive ecosystems.Read moreRead less